A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

Inclusion Criteria:

Must be 18 years or older
Eastern Cooperative Oncology Group performance status of 0-1
Adequate organ function
At least 1 prior line of therapy

Exclusion Criteria:

Concurrent enrollment in another clinical study, unless in follow-up period or it is an observational study
Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
Prior treatment with immunotherapy